Celgene’s Imnovid and Abraxane recommended for use in Ireland
29 February 2016 | By Victoria White
Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane...
List view / Grid view
News
Tremelimumab mesothelioma trial fails to meet primary endpoint
29 February 2016 | By Victoria White
DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival...
Future proofing – Part 1. Modularity and flexibility – New LAB.line tablet hardness testers
29 February 2016 | By Arwid Ischi, Charles Ischi AG | Kraemer Elektronik
What requirements need to be met by a tablet testing system to guarantee a successful product release? Is it dependable upon the testing system’s quality, speed, technology, flexibility or safety? Kraemer and Ischi explain...
Boehringer Ingelheim launches two initiatives to help those living with IPF
29 February 2016 | By Victoria White
Boehringer Ingelheim's new initiatives are dedicated to raising awareness of IPF, a rare disease that is frequently misdiagnosed and little understood...
Roche provides update on two Phase III studies of lebrikizumab in asthma
29 February 2016 | By Victoria White
LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab...
Brivaracetam launches in the UK as a new option for patients with uncontrolled epilepsy
29 February 2016 | By Victoria White
UCB’s Briviact (brivaracetam) has been authorised in the UK as an add-on treatment for partial onset seizures with or without secondary generalised seizures...
Industrial pharmaceutical sieves for powders at GSK
GlaxoSmithKline is improving process efficiency in the production of pharmaceutical powders at its “centre of excellence” plant in Dartford, Kent, by investing in nine new industrial pharmaceutical sieves fitted with the Vibrasonic® Deblinding System from Russell Finex...
CHMP adopts positive opinion of AbbVie’s Viekirax + Exviera in HCV
26 February 2016 | By Victoria White
The CHMP opinion of the Type-II variation application for Viekirax + Exviera is supported by data from the Phase 3b TURQUOISE-III study...
CHMP adopts positive opinion for Lilly’s ixekizumab
26 February 2016 | By Victoria White
Ixekizumab is an IgG4 monoclonal antibody that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor...
CHMP adopts positive opinion of Opdivo in NSCLC and RCC
26 February 2016 | By Victoria White
Both indications are supported by Phase 3 studies in which Opdivo demonstrated a survival benefit versus a standard of care...
Janssen announces results from its ongoing LATTE-2 study
26 February 2016 | By Victoria White
The LATTE-2 study showed that a regimen of two investigational long-acting, intramuscular (IM) formulations of HIV medicines had comparable antiviral activity to 3-drug oral antiretroviral therapy in HIV-1 infected adults...
CHMP adopts positive opinion of haemophilia B treatment, Alprolix
26 February 2016 | By Victoria White
Alprolix is a recombinant clotting factor therapy developed for haemophilia B by fusing factor IX to the Fc portion of immunoglobulin G subclass 1...
CHMP adopts positive opinion of Gilead’s Descovy
26 February 2016 | By Victoria White
Descovy is an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents in combination with other HIV antiretroviral agents...
Encouraging efficacy and safety results for AcelRx’s ARX-04
26 February 2016 | By Victoria White
The safety and efficacy profile observed in the Phase III study is consistent with previous trial results for ARX-04...
Eisai criticises NHSE for further delaying access to cancer treatments
26 February 2016 | By Victoria White
New licensed drugs that have been denied access since May 2015 will have to wait until at least July 2016 before they can be considered for the new Cancer Drug Fund...
